Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure

Clonal evolution in a patient with CML detected by FISH precedes imatinib treatment failure

Bibliographic Details
Main Authors:	Cervera Eduardo, Hurtado Rafael, Candelaria Myrna, Martínez Arturo, Vargas Pablo, Salles Maria Teresa, Gutierrez Olga, Cruz Judith, Enriquez Virginia
Format:	Article
Language:	English
Published:	BMC 2007-02-01
Series:	BMC Cancer

Similar Items

Survival of Patients with CML on Imatinib Experience with 44 Iraqi Patients
by: Ali M. Jawad, et al.
Published: (2008-10-01)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-04-01)

Systems-pharmacology dissection of a drug synergy in imatinib-resistant CML
by: Winter, Georg E, et al.
Published: (2014)

Does thyroid dysfunction happen in CML patients receiving Imatinib for treatment?
by: Hossein Rahimi, et al.
Published: (2015-01-01)

PDGFR-β mediated growth failure in pediatric CML cases on Imatinib
by: Prakamya Gupta, et al.
Published: (2020-09-01)

Nilotinib after resistance to imatinib in CML patients with Wolf-Parkinson White syndrome
by: Massimo Breccia
Published: (2015-10-01)

The Role of STAT5 in Tyrosine Kinase Inhibitor (IMATINIB) Resistance in CML Patients
by: Anastasia Putri, et al.
Published: (2019-10-01)

Efficacy of nilotinib therapy in patient with CML diagnosed in pre-TKI era and resistant to imatinib
by: Ivana Pierri, et al.
Published: (2015-10-01)

Determination of imatinib intracellular uptake in leukocytes as a prognostic factor in cML therapy
by: Eva Kralj, et al.
Published: (2012-12-01)

Immunological monitoring of newly diagnosed CML patients treated with bosutinib or imatinib first-line
by: Anna Kreutzman, et al.
Published: (2019-09-01)

Clonal Evolution and Blast Crisis Correlate with Enhanced Proteolytic Activity of Separase in BCR-ABL b3a2 Fusion Type CML under Imatinib Therapy.
by: Wiltrud Haaß, et al.
Published: (2015-01-01)

CASE REPORT: CML PROGRESSION TO AML-MR WITH CLONAL CHROMOSOMAL ABNORMALITIES
by: S Lanes, et al.
Published: (2023-10-01)

Comparative pharmacokinetic evaluation and bioequivalence study of three different formulations of Imatinib Mesylate in CML patients
by: Ehsan Mohajeri, et al.
Published: (2016-02-01)

Imatinib improves survival of CML patients in accelerated phase: A 48-month follow-up
by: Juliana Todaro, et al.
Published: (2006-03-01)

WT1 PEPTIDE VACCINATION IN COMBINATION WITH IMATINIB THERAPY FOR A PATIENT WITH CML IN THE CHRONIC PHASE
by: Miwako Narita, Masayoshi Masuko, Tohri Kurasaki, Toshiki Kitajima, Shoko Takenouchi, Anri Saitoh, Norihiro Watanabe, Tatsuo Furukawa, Ken Toba, Ichiro Fuse, Yoshifusa Aizawa, Manabu Kawakami, Yoshihiro Oka, Haruo Sugiyama, Masuhiro Takahashi
Published: (2010-01-01)

Efficacy of nilotinib in a patient in late chronic phase CML, intolerant to imatinib and resistant to dasatinib
by: Emilio Usala
Published: (2015-10-01)

Discontinuation of Imatinib in Children with Chronic Myeloid Leukemia: A Study from the International Registry of Childhood CML
by: Frédéric Millot, et al.
Published: (2021-08-01)

Imatinib Mesylate (STI 571) – A New Oral Target Therapy For Chronic Myelogenous Leukemia (CML)
by: Ladislav Chrobák, et al.
Published: (2003-01-01)

Determination of the Cut-off Value for Imatinib Plasma Levels Linked to Occurrence of Bone Pain in CML Patients
by: Hamza MS, et al.
Published: (2022-05-01)

Investigation of the mechanism of USP28-mediated IFITM3 elevation in BCR-ABL-dependent imatinib resistance in CML
by: Zilin Li, et al.
Published: (2024-04-01)

Nilotinib efficacy and safety in CML patient with Parossistic Sopraventricular Tachycardia (PSVT), after sub-optimal response to imatinib
by: Stefana Impera, et al.
Published: (2015-10-01)

ERK2, but not ERK1, mediates acquired and "de novo" resistance to imatinib mesylate: implication for CML therapy.
by: Clara I Aceves-Luquero, et al.
Published: (2009-07-01)

Nilotinib early switch efficacy in non-optimal responder CML patient after first line imatinib treatment
by: Ferdinando Porretto
Published: (2015-10-01)

CircRNA Microarray Profiling Reveals hsa_circ_0058493 as a Novel Biomarker for Imatinib-Resistant CML
by: An-Ni Zhong, et al.
Published: (2021-09-01)

Up-regulation of miR-140 enhances the sensitivity of human CML cell strain KBM5R to imatinib
by: ZHENG Yan, LI Lan, GAO Qiu-ying, NIU Ben, ZHANG Wei-hua
Published: (2022-09-01)

PB1898: BONE MARROW APLASIA – A RARE COMPLICATION OF IMATINIB THERAPY IN CML PATIENTS: ABOUT A CASE
by: W. chawad, et al.
Published: (2022-06-01)

Bullous Pemphigoid Occurring after Stopping Imatinib Therapy of CML: Is a Continuation of Post-Treatment Follow-Up Needed?
by: Alexander Yakobson, et al.
Published: (2023-09-01)

Investigation of the Effect of Imatinib and Hydroxyurea Combination Therapy on Hematological Parameters and Gene Expression in Chronic Myeloid Leukemia (CML) Patients
by: Esraa K. Al-Amleh, et al.
Published: (2022-08-01)

Efficacy of nilotinib in a young patient with high Sokal risk CML Ph+ in treatment failure after high dose imatinib
by: Sabina Russo, et al.
Published: (2015-10-01)

Distribution of common BCR-ABL fusion transcripts and their impact on treatment response in Imatinib treated CML patients: A study from India
by: Sudha Sazawal, et al.
Published: (2019-01-01)

FISH mapping of Philadelphia negative <it>BCR/ABL1 </it>positive CML
by: Marin David, et al.
Published: (2008-07-01)

AMPK-induced novel phosphorylation of RUNX1 inhibits STAT3 activation and overcome imatinib resistance in chronic myelogenous leukemia (CML) subjects
by: Meher Bolisetti Gayatri, et al.
Published: (2023-10-01)

Induction of DNMT1-dependent demethylation of SHP-1 by the natural flavonoid compound Baicalein overcame Imatinib-resistance in CML CD34+ cells
by: Xuefen Xu, et al.
Published: (2023-03-01)

Progress with interferon in CML--results of the MRC UK CML III study.
by: Shepherd, P, et al.
Published: (1996)

HIF2-α Expression in CML Patients Receiving Hydroxyurea Prior to Imatinib That Achieved Major Molecular Response (MMR) versus in Those Not Achieving MMR
by: Rinaldi I, et al.
Published: (2024-02-01)

Clonal evolution of preleukemic hematopoietic stem cells precedes human acute myeloid leukemia.
by: Jan, M, et al.
Published: (2012)

International CML forum
by: A. G. Turkina
Published: (2022-11-01)

PB1899: DEVELOPMENT AND VALIDATION OF A PREDICTIVE SCORING SYSTEM FOR THE PROGNOSIS IN PATIENTS WITH CHRONIC MYELOID LEUKEMIA (CML) IN CHRONIC PHASE RECEIVING FIRST-LINE IMATINIB
by: M. Bektaş, et al.
Published: (2022-06-01)

The role of miRNA -150 between different BCR-ABL p210 transcript levels and between different levels of imatinib optimal response in CML patients
by: Kawthar Ali Radhi, et al.
Published: (2023-03-01)

Acompanhamento farmacoterapêutico dos pacientes com leucemia mieloide crônica em uso de mesilato de imatinibe na Universidade Federal do Ceará The pharmacotherapeutic follow- up of patients with chronic myeloid leukemia (CML) on imatinib mesylate therapy
by: Sterfen S. Aquino, et al.
Published: (2009-01-01)